PubMed:16371368 / 0-318 JSONTXT

{"project":"sonoma2","denotations":[{"id":"T-0","span":{"begin":108,"end":117},"obj":"VAR"},{"id":"T-1","span":{"begin":121,"end":126},"obj":"GENE"},{"id":"T-2","span":{"begin":144,"end":149},"obj":"REG"},{"id":"T-3","span":{"begin":150,"end":165},"obj":"POSREG"},{"id":"T-4","span":{"begin":173,"end":191},"obj":"MPA"},{"id":"T-5","span":{"begin":202,"end":212},"obj":"REG"},{"id":"T-6","span":{"begin":222,"end":231},"obj":"DISEASE"},{"id":"T-7","span":{"begin":246,"end":278},"obj":"DISEASE"},{"id":"T-8","span":{"begin":289,"end":302},"obj":"REG"}],"relations":[{"id":"R-0","pred":"CauseOf","subj":"T-0","obj":"T-2"},{"id":"R-1","pred":"CauseOf","subj":"T-0","obj":"T-3"},{"id":"R-3","pred":"ThemeOf","subj":"T-1","obj":"T-0"},{"id":"R-4","pred":"ThemeOf","subj":"T-4","obj":"T-3"},{"id":"R-5","pred":"ThemeOf","subj":"T-4","obj":"T-5"},{"id":"R-6","pred":"ThemeOf","subj":"T-6","obj":"T-3"},{"id":"R-7","pred":"ThemeOf","subj":"T-6","obj":"T-5"},{"id":"R-8","pred":"ThemeOf","subj":"T-6","obj":"T-8"},{"id":"R-10","pred":"ThemeOf","subj":"T-7","obj":"T-2"},{"id":"R-11","pred":"ThemeOf","subj":"T-7","obj":"T-3"},{"id":"R-12","pred":"ThemeOf","subj":"T-7","obj":"T-5"},{"id":"R-13","pred":"ThemeOf","subj":"T-7","obj":"T-8"}],"text":"Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling.\nMutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensiti"}

{"project":"sonoma","denotations":[{"id":"T-0","span":{"begin":0,"end":7},"obj":"REG"},{"id":"T-1","span":{"begin":33,"end":49},"obj":"POSREG"},{"id":"T-2","span":{"begin":50,"end":58},"obj":"VAR"},{"id":"T-3","span":{"begin":62,"end":79},"obj":"GENE"},{"id":"T-4","span":{"begin":108,"end":117},"obj":"VAR"},{"id":"T-5","span":{"begin":121,"end":138},"obj":"GENE"},{"id":"T-6","span":{"begin":144,"end":149},"obj":"REG"},{"id":"T-7","span":{"begin":150,"end":165},"obj":"POSREG"},{"id":"T-8","span":{"begin":173,"end":191},"obj":"MPA"},{"id":"T-9","span":{"begin":202,"end":212},"obj":"REG"},{"id":"T-10","span":{"begin":222,"end":231},"obj":"DISEASE"},{"id":"T-11","span":{"begin":246,"end":278},"obj":"DISEASE"},{"id":"T-12","span":{"begin":289,"end":302},"obj":"REG"}],"relations":[{"id":"R-0","pred":"CauseOf","subj":"T-0","obj":"T-2"},{"id":"R-1","pred":"ThemeOf","subj":"T-0","obj":"T-3"},{"id":"R-2","pred":"CauseOf","subj":"T-1","obj":"T-2"},{"id":"R-3","pred":"ThemeOf","subj":"T-1","obj":"T-3"},{"id":"R-4","pred":"ThemeOf","subj":"T-2","obj":"T-3"},{"id":"R-5","pred":"ThemeOf","subj":"T-4","obj":"T-5"},{"id":"R-6","pred":"CauseOf","subj":"T-4","obj":"T-6"},{"id":"R-7","pred":"CauseOf","subj":"T-4","obj":"T-7"},{"id":"R-8","pred":"CauseOf","subj":"T-4","obj":"T-9"},{"id":"R-9","pred":"CauseOf","subj":"T-4","obj":"T-12"},{"id":"R-11","pred":"A","subj":"T-5","obj":"T-10"},{"id":"R-12","pred":"A","subj":"T-5","obj":"T-11"},{"id":"R-13","pred":"ThemeOf","subj":"T-6","obj":"T-8"},{"id":"R-14","pred":"ThemeOf","subj":"T-6","obj":"T-10"},{"id":"R-15","pred":"ThemeOf","subj":"T-6","obj":"T-11"},{"id":"R-16","pred":"ThemeOf","subj":"T-7","obj":"T-8"},{"id":"R-17","pred":"ThemeOf","subj":"T-7","obj":"T-9"},{"id":"R-18","pred":"ThemeOf","subj":"T-7","obj":"T-10"},{"id":"R-19","pred":"ThemeOf","subj":"T-7","obj":"T-11"},{"id":"R-20","pred":"ThemeOf","subj":"T-8","obj":"T-9"},{"id":"R-21","pred":"ThemeOf","subj":"T-8","obj":"T-12"},{"id":"R-23","pred":"ThemeOf","subj":"T-9","obj":"T-10"},{"id":"R-24","pred":"ThemeOf","subj":"T-9","obj":"T-11"},{"id":"R-25","pred":"ThemeOf","subj":"T-9","obj":"T-12"},{"id":"R-26","pred":"ThemeOf","subj":"T-10","obj":"T-12"},{"id":"R-28","pred":"ThemeOf","subj":"T-11","obj":"T-12"}],"text":"Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling.\nMutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensiti"}

{"project":"sentences","denotations":[{"id":"T1","span":{"begin":0,"end":107},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling.\nMutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensiti"}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":150,"end":165},"obj":"HP_0000752"},{"id":"T2","span":{"begin":222,"end":231},"obj":"HP_0001909"},{"id":"T3","span":{"begin":246,"end":278},"obj":"HP_0012209"},{"id":"T4","span":{"begin":270,"end":278},"obj":"HP_0001909"}],"text":"Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling.\nMutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensiti"}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"16371368-0#62#67#gene5781","span":{"begin":62,"end":67},"obj":"gene5781"},{"id":"16371368-0#13#21#diseaseC0023418","span":{"begin":13,"end":21},"obj":"diseaseC0023418"},{"id":"16371368-1#138#170#diseaseC0349639","span":{"begin":246,"end":278},"obj":"diseaseC0349639"}],"relations":[{"id":"62#67#gene578113#21#diseaseC0023418","pred":"associated_with","subj":"16371368-0#62#67#gene5781","obj":"16371368-0#13#21#diseaseC0023418"}],"text":"Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling.\nMutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensiti"}

{"project":"kaiyin_test","denotations":[{"id":"T1","span":{"begin":108,"end":117},"obj":"Var"},{"id":"T2","span":{"begin":121,"end":126},"obj":"Gene"},{"id":"T3","span":{"begin":127,"end":138},"obj":"Enzyme"},{"id":"T4","span":{"begin":150,"end":165},"obj":"PosReg"},{"id":"T5","span":{"begin":173,"end":191},"obj":"MPA"},{"id":"T33","span":{"begin":216,"end":231},"obj":"Disease"},{"id":"T34","span":{"begin":246,"end":278},"obj":"Disease"}],"relations":[{"id":"R1","pred":"ThemeOf","subj":"T3","obj":"T2"},{"id":"R2","pred":"ThemeOf","subj":"T2","obj":"T1"},{"id":"R3","pred":"CauseOf","subj":"T1","obj":"T4"},{"id":"R4","pred":"ThemeOf","subj":"T5","obj":"T4"}],"text":"Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling.\nMutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensiti"}

{"project":"name_no","denotations":[{"id":"T1","span":{"begin":108,"end":117},"obj":"Var"},{"id":"T2","span":{"begin":121,"end":126},"obj":"Gene"},{"id":"T3","span":{"begin":127,"end":138},"obj":"Enzyme"},{"id":"T4","span":{"begin":150,"end":165},"obj":"PosReg"},{"id":"T5","span":{"begin":173,"end":191},"obj":"MPA"},{"id":"T33","span":{"begin":216,"end":231},"obj":"Disease"},{"id":"T34","span":{"begin":246,"end":278},"obj":"Disease"}],"relations":[{"id":"R1","pred":"ThemeOf","subj":"T3","obj":"T2"},{"id":"R2","pred":"ThemeOf","subj":"T2","obj":"T1"},{"id":"R3","pred":"CauseOf","subj":"T1","obj":"T4"},{"id":"R4","pred":"ThemeOf","subj":"T5","obj":"T4"}],"text":"Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling.\nMutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensiti"}

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":62,"end":67},"obj":"gene:5781"},{"id":"T1","span":{"begin":13,"end":21},"obj":"disease:C0023418"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling.\nMutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensiti"}

{"project":"mondo_disease","denotations":[{"id":"T1","span":{"begin":13,"end":21},"obj":"Disease"},{"id":"T2","span":{"begin":222,"end":231},"obj":"Disease"},{"id":"T3","span":{"begin":246,"end":278},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0005059"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0005059"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0011908"}],"text":"Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling.\nMutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensiti"}

{"project":"HP-phenotype","denotations":[{"id":"T1","span":{"begin":13,"end":21},"obj":"Phenotype"},{"id":"T2","span":{"begin":246,"end":278},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"HP:0001909"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"HP:0012209"}],"namespaces":[{"prefix":"HP","uri":"http://purl.obolibrary.org/obo/HP_"}],"text":"Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling.\nMutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensiti"}

{"project":"NCBITAXON","denotations":[{"id":"T1","span":{"begin":216,"end":221},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"9606"}],"text":"Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling.\nMutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensiti"}

{"project":"Anatomy-UBERON","denotations":[{"id":"T1","span":{"begin":246,"end":254},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0007021"}],"text":"Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling.\nMutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensiti"}